Antibiotic resistance

New Study Reports Cannabinoid Effective Against MRSA

Nemus Bioscience and the University of Mississippi report significant anti-MRSA synergy data utilizing proprietary cannabinoid-based anti-infective platforms.

New MRSA Defense: New Study Reports Cannabinoid Effective Against...
New MRSA Defense: New Study Reports Cannabinoid Effective Against Antibiotic-Resistant MRSA
Source: Newswise
New MRSA Defense: New Study Reports Cannabinoid Effective Against...
New MRSA Defense: New Study Reports Cannabinoid Effective Against Antibiotic-Resistant MRSA
Source: Newswise

Researchers have found that cannabinoid-based therapies have unique anti-bacterial properties that fight MSRA and other infectious bacteria. In vitro studies demonstrated that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA species tested included community acquired- (CA-MRSA), healthcare-acquired- (HA-MRSA), and mupirocin-resistant (MR-MRSA) strains of MRSA. 

Researchers also found that using unique strategic cannabinoid-based cocktails, fractional-inhibitory concentration (FIC) levels demonstrating synergy between mixtures of individual cannabinoid-based components ranged from 0.06 to 0.28. FIC findings below 0.5 indicate significant killing potential of the mixture. The work was led by NEMUS Bioscience, Inc. and the company's discovery and research partner, the University of Mississippi (UM).

Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research (NCNPR) at the University of Mississippi commented: "Historically, many types of anti-infective compounds are derived from plants so to have a series of cannabinoid-related compounds exhibit activity against this dangerous pathogen is in keeping with prior efforts of drug development. I believe that these compounds, in addition to the bacterial killing capability, could also offer benefits associated with anti-inflammatory and anti-fibrotic properties that could enhance healing, especially against an organism associated with skin and soft tissue infections. The University, in conjunction with Nemus, is looking to expand the anti-infective capabilities of this series of compounds."

Recently, the World Health Organization (WHO) placed MRSA on their list as one of the top six organisms that pose a global public health threat. "This anti-infective platform will constitute the NB3000 series of Nemus molecules and formulations.  While there are a number of compounds in the development pipeline against MRSA, we believe that this family of drug candidates could possess an excellent safety profile in addition to efficacy in neutralizing this bacterium," stated Brian Murphy, M.D., C.E.O. and Chief Medical Officer of Nemus. "These unique botanically derived components establish an anti-infective platform which could potentially be expanded into other types of bacteria, as well as viruses, and fungi."

Nemus will work with Dr. Elsohly, the University lead researcher on this project, to have this data submitted to a future scientific meeting and anticipates performing further testing against a variety of other bacterial species. Commercially, the company looks to actively pursue partnering opportunities for these candidate molecules. “This work highlights the importance of Nemus' relationship with the University which has significant experience and intellectual capital related to cannabinoid chemistry and physiology, dating back to 1968," added Dr. Murphy

Source: Newswise

31.03.2017

More on the subject:
Read all latest stories

Related articles

Research

Path to deadly sepsis varies by bacterial infection

Sepsis remains a common and deadly condition that occurs when the body reacts to an infection in the bloodstream. Scientists know little about the early stages of the condition; however, physicians…

Innovation

A real time saver at the highest level of molecular diagnostics – the eazyplex® platform!

This platform enables you to perform high class molecular diagnostics at an unbelievable speed. All assay run times are as short as 15 to 30 minutes, depending on the sample material. The lyophilised…

Superbug MRSA

Unlocking the secrets of Staph's immune bypass

For years, medical investigators have tried and failed to develop vaccines for a type of staph bacteria associated with the deadly superbug MRSA. But a new study by Cedars-Sinai investigators shows…

Related products

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd